BMJ 2021, 23 RCTs, n=1357, including unpublished data from five trials. Low-carbohydrate defined <26% of energy or <130 g/day — materially stricter than the <45% used by broader reviews.
The answer depends entirely on what “remission” means
| Definition | 6 months | 12 months |
|---|---|---|
| HbA1c <6.5% | RD 0.32 (0.17 to 0.47), RR 1.87 (1.18 to 2.97), 8 RCTs, n=264, Moderate | RD 0.10 (-0.02 to 0.21), 3 RCTs, n=171, Moderate |
| HbA1c <6.5% AND no diabetes medication | RD 0.05 (-0.05 to 0.14), 5 RCTs, n=199, Low | RD -0.04 (-0.16 to 0.09), 2 RCTs, n=126, Low |
[EXTRACTED (Goldenberg - Low Carbohydrate Diets T2D Remission 2021) Table 2; Results]
This is the finding. The headline 32 per 100 more remissions — an NNT of about 3 — is remission with medication allowed to continue. Under the definition that also requires coming off medication, the effect is never statistically significant at any timepoint, and the 12-month point estimate is negative.
But the stratum matters, and this is where the headline needs qualifying. In trials that excluded insulin users, medication-free remission is significant: RD 0.20 (0.03 to 0.38), NNT 5, against 0.00 (-0.07 to 0.07) where insulin users were included (test for subgroup difference P=0.03). For the medication-permitted definition the split is starker still — 0.51 (0.36 to 0.65) vs 0.14 (0.03 to 0.25), P<0.001. [EXTRACTED (Goldenberg - Low Carbohydrate Diets T2D Remission 2021) Results] So “never significant” holds for the pooled medication-free estimate and not for the non-insulin stratum — which is the stratum in which a low-carbohydrate diet would most plausibly be offered. Per the telos’s layer-2 rule the narrowest credible reference class is the one to quote.
And the two definitions do not draw on the same trials. Only 7 of 23 trials (30%) permitted medication reduction and reported usable data, so the medication-free estimates come from a structurally different set of trial designs, not from a stricter reading of the same evidence. [INFERRED (Goldenberg - Low Carbohydrate Diets T2D Remission 2021) — entailment from the trial counts and the Limitations note on medication permission.]
Most benefits attenuate by 12 months — but not all
| Outcome | 6 months | 12 months | Certainty |
|---|---|---|---|
| Weight | MD -3.46 kg (-5.25 to -1.67), 18 RCTs | MD +0.29 kg (-1.02 to 1.60), 7 RCTs | Moderate |
| HbA1c | MD -0.47% (-0.60 to -0.34), 17 RCTs | MD -0.23% (-0.46 to 0.00), 8 RCTs | High -> Moderate |
| Fasting glucose | MD -0.73 mmol/L (-1.19 to -0.27) | MD 0.06 mmol/L higher (-0.37 to 0.48), 6 RCTs | Moderate |
| Medication reduction | RD 0.24 (0.12 to 0.35), 7 RCTs | RD 0.33 (-0.00 to 0.66), 3 RCTs | Moderate -> Low |
Medication reduction and triglycerides go the other way (0.24 -> 0.33; -0.30 -> -0.32), so the source’s own wording is the accurate one: “most benefits diminished at 12 months.”
[EXTRACTED (Goldenberg - Low Carbohydrate Diets T2D Remission 2021) Table 3; Results]
The HbA1c estimate at 6 months is the only High-certainty row among the primary outcomes. Table 3 carries five more (LDL at 6 months, HDL and triglycerides at both timepoints).
Attenuation is already visible inside the six-month window — but this is a POST HOC analysis and carries less weight than the a-priori subgroups above. The review is explicit about its provenance: “On the basis of comments from peer reviewers, we did a post hoc analysis on remission at six (+/-3) months”, and hedges its reading (“evidence suggested larger treatment effects… suggesting that shorter term trials may be an effect modifier”). Trials of 3 to <6 months give RD 0.49 (0.30 to 0.68); trials of 6 to 9 months give 0.25 (0.08 to 0.42). Medication-free: 0.20 (0.03 to 0.38) vs 0.00 (-0.07 to 0.07). [EXTRACTED (Goldenberg - Low Carbohydrate Diets T2D Remission 2021) Limitations]
Note a coincidence worth not over-reading: the medication-free figures here (0.20 / 0.00) are numerically identical to the insulin-exclusion subgroup’s. That is consistent with the two splits being near-coextensive — the non-insulin trials largely being the short ones — in which case this is one finding presented twice, not two. The paper’s supplementary tables would settle it; the wiki does not hold them.
Medication is handled four ways at once, and this is the transferable move
Not adjusted for — co-reported. The review’s stated reasoning:
“Reductions in medication may blunt the effect on mean HbA1c levels, biasing results towards the null and masking any effect; however, any improvement can still be captured if reduction of medication is included as an outcome of interest.” [EXTRACTED (Goldenberg - Low Carbohydrate Diets T2D Remission 2021) Limitations]
So medication appears (1) inside two of the four remission definitions, (2) as a standalone outcome, (3) as a named bias mechanism, and (4) as a subgroup variable. The HbA1c mean difference and the medication-reduction risk difference are two projections of one underlying effect, and neither alone is complete. Any claim built on the HbA1c figure alone understates the glycaemic effect by an amount the review does not quantify.
Generalizes past diabetes: wherever a treatment lets people reduce a co-intervention, the outcome measured under fixed co-intervention is biased toward the null, and the fix is to report the co-intervention change as its own outcome rather than to adjust it away.
Harms, and how firm they are
- LDL at 12 months: MD 0.14 mmol/L (-0.00 to 0.28), 6 studies, Moderate — above the review’s own 0.10 mmol/L threshold, so labelled a clinically important worsening, though P=0.05. At 6 months LDL is flat (0.02) at High certainty.
- Quality of life at 12 months: MD 3.10 (-2.03 to 8.23), threshold 1, Low certainty. Rests on a single trial of 116 people, with an interval spanning a benefit twice the threshold and a harm eight times it, judged important on the point estimate alone. The 6-month estimate points the other way and comes from 4 trials — so the apparent reversal is partly a change of study set, not a trajectory. [INFERRED (Goldenberg - Low Carbohydrate Diets T2D Remission 2021) — entailment from the differing trial counts at the two timepoints.]
- Adverse events: no significant increase, but “poorly reported among trials and the certainty of evidence for safety ranges from low to very low.”
What the review tells clinicians to do
“clinicians might consider short term LCDs for management of type 2 diabetes, while actively monitoring and adjusting diabetes medication as needed.” [EXTRACTED (Goldenberg - Low Carbohydrate Diets T2D Remission 2021) Conclusions]
Two conditions attached — short term, and active medication management. Note the reason for the time limit is partly external to this review’s own evidence: it cites a cohort review suggesting long-term low-carbohydrate diets are associated with increased mortality.
The summary box vs the body — reconciled, not a defect
The key-messages box claims “large and clinically important improvements in weight loss, triglycerides, and insulin resistance were also seen, without adverse events.” The Discussion’s own threshold tally says something narrower: “Among 10 continuous outcomes, two showed improvements that met or surpassed the MCID at six months (triglycerides, insulin resistance)… At 12 months… two had a clinically important worsening (quality of life, low density lipoprotein cholesterol).”
This reconciles rather than conflicting. The Methods pre-specify that “if the risk of bias sensitivity analysis was credible, we focused our results on those studies at low risk” — and weight was the outcome where that applied, giving MD -7.41 kg (-9.75 to -5.08) in low-risk-of-bias trials, which does surpass the 4.4 kg threshold. And “adverse events” is a named outcome class in this review (total and serious AEs), on which nothing significant was found; the 12-month LDL and quality-of-life worsening are continuous outcomes, and the Conclusions state them plainly. The box is the review applying its own stated method, not drifting from its body.
On the HbA1c threshold. The main text prints thresholds for eight continuous outcomes and not for the two glycaemic ones; the full table is in a supplement not held here. But the question is answerable anyway, from the review’s own tally: of ten continuous outcomes, only triglycerides and insulin resistance met or surpassed their threshold at six months. HbA1c is one of the ten. So -0.47% did not clear the review’s own bar — a decision-relevant fact, and one recoverable by counting the outcomes rather than concluding it unknowable because the main text does not say so directly.
The mechanism this review does not isolate — weight loss, not carbohydrate per se
Low-carbohydrate diets cause weight loss, and this review’s remission effect attenuates to null by 12 months in step with its weight advantage (weight MD -3.46 kg at 6 months -> +0.29 kg at 12 months). A remission effect that decays as the weight advantage decays is consistent with a weight-loss effect delivered via a low-carb route, rather than a carbohydrate effect independent of weight. DiRECT (Lean 2018) makes this near-decisive: it achieves 46% remission on an 825-853 kcal/day formula diet that is 59% carbohydrate — the opposite of low-carb — with remission scaling monotonically with kilograms lost (0% at weight gain -> 86% at >=15 kg). [EXTRACTED (Lean - DiRECT T2D Remission 2018) Results; Findings] So carbohydrate restriction is not necessary for remission, and is best read as one lever for the weight loss that drives remission — with no evidence here that it adds a remission effect beyond the weight loss it produces (an added glycaemic contribution is untested, not excluded). A person should optimize for the weight loss they can sustain, by whichever route they will adhere to -> Total Diet Replacement and Type 2 Diabetes Remission.
Limits
- Small numbers behind the headline: the 6-month remission estimate is 8 trials, n=264; by 12 months it is 3 trials, n=171.
- Only 30% of trials permitted medication reduction, which constrains the definition that matters most.
- The mortality caution is imported from cohort evidence, not tested here.
- Same population, adjacent condition: this stratum overlaps heavily with fatty liver — insulin resistance is the shared hub (MASLD carries a >2x risk of incident T2D), and the weight-loss and glycemia levers here are the same ones that reduce liver fat -> Fatty Liver MASLD and Weight Loss.
- A guidance benchmark is needed to run the guidance-null on this question; both are staged. AWAITS ADA-EASD - Nutrition Therapy for Diabetes 2019 AWAITS EASD - DNSG Dietary Management of Diabetes 2023